{"id":740026,"date":"2023-03-14T16:23:17","date_gmt":"2023-03-14T20:23:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-provide-operational-update-and-report-full-year-2022-financial-results-on-march-28-2023\/"},"modified":"2023-03-14T16:23:17","modified_gmt":"2023-03-14T20:23:17","slug":"nanobiotix-to-provide-operational-update-and-report-full-year-2022-financial-results-on-march-28-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-provide-operational-update-and-report-full-year-2022-financial-results-on-march-28-2023\/","title":{"rendered":"Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023"},"content":{"rendered":"
\n

Conference Call and Webcast to be Held at 2:00 P.M CET\/8:00 A.M. EDT on March 29, 2023\u00a0\u00a0<\/p>\n

PARIS and CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) — NANOBIOTIX<\/a> (Euronext: NANO \u2013\u2013 NASDAQ: NBTX \u2013 the \u2018\u2018Company<\/strong>\u2019\u2019), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announces that it will provide an operational update and report its financial results for full-year ending December 31, 2022, on Tuesday, March 28, 2023, after the close of the US market.<\/p>\n

This release will be followed by a conference call and live audio webcast on Wednesday, March 29, 2023, at 2:00 PM CET\/8:00 AM EDT, prior to the open of the US market. During the call, Laurent Levy, chief executive officer, and Bart Van Rhijn, chief financial officer, will briefly review the Company\u2019s year-end results and provide an update on business activities before taking questions from analysts and investors. Investors are invited to email their questions in advance to investors@nanobiotix.com<\/a>.\u00a0<\/p>\n

Details for the call are as follows:<\/p>\n

Dial-In Information:<\/p>\n

Live (US): 1-877-423-9813<\/p>\n

Live France: 0 800 912 848<\/p>\n

Live (international): 1-201-689-8573<\/p>\n

A live webcast of the call may be accessed by visiting the investors section of the Company\u2019s website at www.nanobiotix.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company\u2019s website.<\/p>\n

***<\/p>\n

\n About NBTXR3<\/strong>
\n
NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. The product candidate\u2019s physical mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA, Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors.<\/p>\n

NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) as the primary development pathway. The company-sponsored Phase 1 dose escalation and dose expansion study has produced favorable safety data and early signs of efficacy; and a Phase 3 global registrational study was launched in 2021. In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy\u2014the same population being evaluated in the Phase 3 study.<\/p>\n

Nanobiotix has also prioritized an Immuno-Oncology development program\u2014beginning with a Company-sponsored Phase 1 clinical study evaluating NBTXR3 activated by radiotherapy in combination with anti-PD-1 checkpoint inhibitors for patients with locoregional recurrent or recurrent\/metastatic HNSCC, or lung or liver metastases from any primary cancer eligible for anti-PD-1 therapy.<\/p>\n

Given the Company\u2019s focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a strategic collaboration strategy with world class partners to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several Phase 1 and Phase 2 studies to evaluate NBTXR3 across tumor types and therapeutic combinations.<\/p>\n

\n About NANOBIOTIX: <\/strong>
\n
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company\u2019s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.<\/p>\n

Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, and Germany. Nanobiotix has been listed on Euronext: Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020.<\/p>\n

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. The company’s resources are primarily devoted to the development of its lead product candidate\u2013NBTXR3\u2014which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify\u00ae<\/sup>.<\/p>\n

For more information about Nanobiotix, visit us at www.nanobiotix.com<\/a> or follow us on LinkedIn<\/a> and Twitter<\/a><\/p>\n

\n Contacts<\/strong>\n <\/p>\n\n\n\n\n\n
\n Nanobiotix<\/em>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
\n
\n Communications Department<\/strong>
\n
\n Brandon Owens<\/em>
\n
\n VP, Communications<\/em>
\n
+1 (617) 852-4835
contact@nanobiotix.com<\/a><\/u><\/p>\n<\/td>\n		\n
\n Investor Relations Department <\/strong>
\n
\n Kate McNeil<\/em>
\n
\n SVP, Investor Relations<\/em>
\n
+1 (609) 678-7388
investors@nanobiotix.com<\/a><\/u><\/p>\n<\/td>\n		\u00a0<\/td>\n<\/tr>\n
\n Media Relations<\/em>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
\n
FR \u2013Ulysse Communication
<\/strong>Pierre-Louis Germain
+ 33 (0) 6 64 79 97 51
plgermain@ulysse-communication.com<\/a><\/p>\n<\/td>\n		Global \u2013 LifeSci Advisors<\/strong>
Ligia Vela-Reid
+44 (0) 7413825310
Lvela-reid@lifesciadvisors.com<\/a><\/u><\/td>\n		\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n Attachment<\/strong>\n <\/p>\n